Abstract Number: 025 • 2023 Pediatric Rheumatology Symposium
Patient- and Center-level Risk Factors for Research Lost to Follow-up Using the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Background/Purpose: Clinical registries are typically envisioned to be representative of a target patient population and reflective of health care delivery practices for said population. Variation…Abstract Number: 059 • 2023 Pediatric Rheumatology Symposium
Update of Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life-threatening clinical problem. Despite recent advances, there remain key unanswered questions…Abstract Number: 062 • 2023 Pediatric Rheumatology Symposium
Assessment of Barriers and Facilitators in Implementation of the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
Background/Purpose: Since 2010, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) has developed 12 consensus treatment plans (CTP) with the aim of reducing treatment variability…Abstract Number: 109 • 2023 Pediatric Rheumatology Symposium
Long-term Safety of Biologics versus Conventional Synthetic Treatments in Systemic Juvenile Idiopathic Arthritis Patients
Background/Purpose: The better understanding of systemic Juvenile Idiopathic Arthritis (sJIA) pathogenesis and availability of new drugs, such as biologic disease-modifying anti-rheumatic drugs (bDMARDs) specifically dedicated…Abstract Number: 115 • 2023 Pediatric Rheumatology Symposium
Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis
Background/Purpose: The LIMIT-JIA trial is the first study of the use of biologic therapy to prevent disease extension in children with newly diagnosed, uncomplicated, oligo-articular…Abstract Number: 120 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up
Background/Purpose: A national registry was set up, enrolling new onset JDM cases in 18 hospitals, during 3-years (2015-2018) with 2-years follow up, in a low…Abstract Number: L09 • ACR Convergence 2022
Impact on Access to Methotrexate in the Post-Roe Era
Background/Purpose: Methotrexate is the first line therapy for RA and is used to treat several other rheumatic and non-rheumatic disorders. In high doses, it can…Abstract Number: 0820 • ACR Convergence 2022
Therapeutic Practices and Outcomes of Chronic Sarcoidosis Arthropathy in the United States: A Nationwide Registry Study
Background/Purpose: Chronic arthropathy is a rare manifestation of sarcoidosis reported in only 0.2% of patients. However, treatment is challenging because no general consensus regarding appropriate…Abstract Number: 1752 • ACR Convergence 2022
Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic and Targeted Synthetic DMARDs in Real World Clinical Practice: Data from BIOBADASER
Background/Purpose: Extensive evidence has confirmed no increased risk of cancer associated to either conventional synthetic DMARDs or anti-TNF in patients with rheumatic diseases. The risk…Abstract Number: 0850 • ACR Convergence 2022
Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are the most commonly used first biologics to treat juvenile idiopathic arthritis (JIA), but it is unknown what subsequent…Abstract Number: 1842 • ACR Convergence 2022
Vaccination in Patients with Autoinflammatory Periodic Syndromes Under Canakinumab – Safety Data Interim Analysis of the RELIANCE Registry
Background/Purpose: Treatment of autoinflammatory periodic syndromes with the interleukin-1β inhibitor canakinumab (CAN) has been shown to be safe and effective in clinical trials and in…Abstract Number: 0855 • ACR Convergence 2022
Change in Short Term Outcomes Following Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: Current recommendations suggest treatment escalation for juvenile idiopathic arthritis (JIA) until the disease activity target is reached, ideally inactive or low disease activity. Our…Abstract Number: 1992 • ACR Convergence 2022
Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Background/Purpose: Pain is a hallmark symptom of RA that impacts patients' quality of life and informs therapeutic decisions that aim to reduce joint inflammation and…Abstract Number: 0888 • ACR Convergence 2022
Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis Patients Before and After Initiation of a First Advanced Therapy. Data from the University of Sherbrooke Registry of Advanced Therapies (USRAT)
Background/Purpose: Uncontrolled inflammation in rheumatoid arthritis (RA) patients increases the risk for incident Ischemic Heart Disease (IHD) and venous thromboembolic (TE) events. Reducing inflammation using…Abstract Number: 1999 • ACR Convergence 2022
Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)
Background/Purpose: Rheumatoid arthritis (RA) treatment response is typically defined using clinician-reported scores and patient global assessments of disease activity (PtGA), but patients may have a…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 18
- Next Page »